Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
433 GBX | -1.37% | -2.26% | +29.84% |
07/05 | AstraZeneca target raised; Antofagasta lowered | AN |
03/05 | AIB GROUP : Stronger revenue growth and a benign cost of risk |
Sales 2024 * | 455.65Cr 495.84Cr 41TCr | Sales 2025 * | 434.04Cr 472.33Cr 39TCr | Capitalization | 1.26TCr 1.37TCr 1,14800Cr |
---|---|---|---|---|---|
Net income 2024 * | 176.2Cr 191.74Cr 16TCr | Net income 2025 * | 156.1Cr 169.87Cr 14TCr | EV / Sales 2024 * | 2.77 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.91 x |
P/E ratio 2024 * |
7.27
x | P/E ratio 2025 * |
7.57
x | Employees | 10,551 |
Yield 2024 * |
5.76% | Yield 2025 * |
6.11% | Free-Float | 68.01% |
Latest transcript on AIB Group plc
1 day | -2.79% | ||
1 week | -2.26% | ||
Current month | -3.67% | ||
1 month | -2.48% | ||
3 months | +14.93% | ||
6 months | +17.42% | ||
Current year | +29.84% |
Managers | Title | Age | Since |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 01/16/01 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 01/13/01 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 19/23/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Pettigrew
CHM | Chairman | 65 | 28/21/28 |
Basil Geoghegan
BRD | Director/Board Member | - | 04/19/04 |
Colin Hunt
CEO | Chief Executive Officer | 54 | 01/16/01 |
Date | Price | Change | Volume |
---|---|---|---|
04/24/04 | 433 | -1.37% | 55 409 |
03/24/03 | 439 | -2.34% | 18,193,380 |
31/24/31 | 449.5 | +2.51% | 793,697 |
30/24/30 | 438.5 | -0.34% | 76,860 |
29/24/29 | 440 | -0.68% | 2,677,648 |
Delayed Quote London S.E., June 04, 2024 at 09:05 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.98% | 58TCr | |
+17.88% | 31TCr | |
+15.97% | 25TCr | |
+19.24% | 21TCr | |
+20.65% | 18TCr | |
+24.83% | 17TCr | |
+8.61% | 16TCr | |
+9.54% | 15TCr | |
-13.23% | 14TCr |
- Stock Market
- Equities
- A5G Stock
- AIBG Stock